PubMed ID:
11576365
Public Release Type:
Journal
Publication Year: 2001
Affiliation: New England Medical Center, Division of Nephrology, Boston, Massachusetts 0211, USA. dmiskulin@lifespan.org
DOI:
https://doi.org/10.1046/j.1523-1755.2001.00954.x
Authors:
Athienites NV,
Hemodialysis (HEMO) Study Group,
Kusek JW,
Levey AS,
Martin AA,
Meyer KB,
Miskulin DC,
Ornt DB,
Yan G
Studies:
Hemodialysis Study
The Hemodialysis (HEMO) Study is a multicenter trial designed to determine whether hemodialysis dose and membrane flux affect survival. Comorbid conditions are also important determinants of survival, and thus, an accurate and reliable method to assess comorbidity was required. Comorbidity was being assessed at baseline and annually in the HEMO Study using the Index of Coexistent Disease (ICED). We describe the instrument, its implementation in the HEMO Study, and the results of comorbidity assessment in the first 1000 randomized patients in the trial.